CBA 150

CBA 150 (Colistimethate Sodium for Injection, USP):

“Simplifies the Solution to Optimize Colistin Therapy”

CBA eequivalent to 150 mg Colistin base activity 360 mg Colistimethate Sodium (4.5 miu) is a FDA approved advance formulation of Colistimethate sodium with simple 2 vial loading dose follow by 150 mg every 12 hourly. It’s a reliable salvage therapy for high risk, culture documented infections & COS Pts. It belongs to a group of antibiotics that are called polymyxins. CBA150 is effective against most Gram-negative bacilli and provide better concentration at the site of infection. Currently CBA150 is imported from Thailand in full finished form.


CBA 150 is indicated for the treatment of acute or chronic infections due to the following sensitive strains of certain gram-negative bacilli: Acinetobacter baumannii, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa including MDR, XDR & ESBL producing gram negative organisms.

Pharmaceutical Form:

CBA 150 is a sterile parenteral antibiotic. Each vial contains: Sterile Lyophilized powder of Colistimethate Sodium eq. to 150 mg Colistin base activity containing theequivalent of 4.5 MIU or 230 mg Colistimethate sodium in single dose vial Pack

Dosage Guidelines:

Adults or Children 12 years or above:-

Initial/Loading Dose: 9 MIU or 300 mg Colistin-Based Activity (CBA) i.e. (2 vials of CBA 150 mg)
Maintenance Dose:- 150 mg (CBA) or 4.5 MIU BID/12 hourly
Without Loading Dose:- 150 mg (CBA) or 4.5 MIU BID/12 hourly

Renal Impairment:- Creatinine Clearance between 10 and 30 ml/min: 150 mg (CBA) or 4.5 MIU over 1 hour per 24 hourly.
Creatinine Clearance <10 ml/min:- 150 mg (CBA) or 4.5 MIU over 1 hour per 48 hourly.


CBA 150 should be stored at or below 30 ˚C and protected from light.

cba150 injection